James Kaye, MD, DrPH
Adjunct Associate Professor
Boston University School of Public Health
Dept of Epidemiology

MD, Stanford University School of Medicine
MPH, Harvard School of Public Health
DrPH, Harvard School of Public Health

James Kaye, MD, DrPH, is a medical oncologist/hematologist, epidemiologist, and Senior Director of Epidemiology at RTI-HS. Dr. Kaye completed an internship and residency in internal medicine at the Beth Israel Hospital in Boston and a fellowship in medical oncology/hematology at the Dana Farber Cancer Institute. He then served on the faculty in the Department of Medicine at Harvard Medical School while practicing medical oncology/hematology and coordinating the clinical research program at Harvard Community Health Plan.

In 1991, Dr. Kaye joined the clinical development group at Genetics Institute, Inc. (later Wyeth, now Pfizer) where he directed clinical trials on several hematology/oncology products, two of which were approved for marketing. He participated in numerous Food and Drug Administration interactions, including investigational new drug and biologic license application submissions, advisory committee presentations, and label negotiations.

Dr. Kaye subsequently completed doctoral training in pharmacoepidemiology with a focus on pharmaceuticals and cancer risk. He was senior epidemiologist at the Boston Collaborative Drug Surveillance Program and a faculty member at Boston University School of Public Health, where he continues to serve as adjunct associate professor of epidemiology.

In 2009, Dr. Kaye joined RTI-HS, where he conducts research on postmarketing safety issues (especially cancer risk) and advises RTI-HS staff on a variety of health economics, biostatistics, and other projects relating to hematology/oncology drugs in development. He has chaired or participated in numerous independent data monitoring committees for clinical trials of drugs for the treatment of cancer or hematologic diseases, and he consults with clients on the assessment of cancer-related safety issues for drugs used in other indications. Dr. Kaye has authored more than 100 articles in the peer-reviewed medical literature.

Senior Director, Epidemiology
RTI Health Solutions

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Goyal RK, Nagar SP, Kabadi SM, Kaye JA, Seal B, Mato AR. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2018 Oct 02; 1-9. PMID: 30277099.
  2. Mytelka DS, Nagar SP, D'yachkova Y, La EM, Kaye JA, Candrilli SD, Kasper B, Lopez-Martin JA, Lorenzo M. Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018; 2018:2020591. PMID: 30297977.
  3. Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. Epidemiology. 2018 Sep; 29(5):e41-e42. PMID: 29794511; DOI: 10.1097/EDE.0000000000000856;.
  4. Handy CE, Quispe R, Pinto X, Blaha MJ, Blumenthal RS, Michos ED, Lima JAC, Guallar E, Ryu S, Cho J, Kaye JA, Comin-Colet J, Corbella X, Cainzos-Achirica M. Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment. Circulation. 2018 Aug 14; 138(7):727-734. PMID: 30359131.
  5. Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct; 124:310-316. PMID: 30119925.
  6. La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom. Eur J Cancer Care (Engl). 2018 Sep; 27(5):e12862. PMID: 29927010.
  7. Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct; 124:298-309. PMID: 29961557.
  8. Nagar SP, Mytelka DS, Candrilli SD, D'yachkova Y, Lorenzo M, Kasper B, Lopez-Martin JA, Kaye JA. Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018; 2018:5467057. PMID: 29977133.
  9. Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegård A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. Drugs Real World Outcomes. 2018 May 07. PMID: 29736842; DOI: 10.1007/s40801-018-0133-1;.
  10. Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. Clin Sarcoma Res. 2018; 8:8. PMID: 29744029; DOI: 10.1186/s13569-018-0094-x;.
Showing 10 of 99 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 99 publications over 22 distinct years, with a maximum of 17 publications in 2018

Contact for Mentoring:

RTI Health Solutions, 307 Waverley Oaks Road, Suite 101
Waltham MA 02452-8413
Google Map

Kaye's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department